Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

2019 ◽  
Vol 14 (2) ◽  
pp. 125-136 ◽  
Author(s):  
Martin Reck ◽  
Geetha Shankar ◽  
Anthony Lee ◽  
Shelley Coleman ◽  
Mark McCleland ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%

2021 ◽  
Author(s):  
Renaud Descourt ◽  
Christos Chouaid ◽  
Maurice Pérol ◽  
Benjamin Besse ◽  
Laurent Greillier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov ( NCT04547504 ).

scholarly journals P3.02b-088 TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations

2017 ◽  
Vol 12 (1) ◽  
pp. S1244-S1245 ◽  
Author(s):  
Inês Guerreiro ◽  
Ana Vitor Silva ◽  
Ana Rodrigues ◽  
Cristina Oliveira ◽  
Inés Pousa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document